Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.37 |
| ▸ | CLK1 | P49759 | 4/20 | 0.37 |
| ▸ | CLK2 | P49760 | 4/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046733 | 0.81 | CLK1 (0.51) | PDE4APDE4BPDE4CPDE4DMAP4K4 | |
| SCHEMBL15430486 | 0.80 | DYRK1B (0.43) | CLK4CLK1CLK2DYRK1BEGFR | |
| SCHEMBL2454453 | 0.78 | ALDH1A1 (0.44) | PDE4APDE4BPDE4CPDE4DMAP4K4 | |
| Hydrochloric Acid SCHEMBL2452975 | 0.77 | ALDH1A1 (0.43) | PDE4APDE4BPDE4CPDE4DMAP4K4 | |
| SCHEMBL12332635 | 0.74 | CLK4 (0.53) | PDE4APDE4BPDE4CPDE4DMAP4K4 | |
| SCHEMBL14878602 | 0.71 | EGFR (0.50) | CLK4CLK1CLK2DYRK1BEGFR | |
| SCHEMBL14878619 | 0.71 | CLK4 (0.39) | MAP4K4CLK4CLK1CLK2DYRK1B | |
| SCHEMBL6764092 | 0.71 | GSK3B (0.43) | PDE4APDE4BPDE4CPDE4DMAP4K4 | |
| SCHEMBL11929436 | 0.71 | CLK4 (0.40) | MAP4K4CLK4CLK1CLK2DYRK1B | |
| SCHEMBL14304406 | 0.69 | MAP4K4 (0.47) | PDE4APDE4BPDE4CPDE4DMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710221-B2 | Process and intermediates for preparing lapatinib | SCINOPHARM TAIWAN, LTD. (TW) | 2014-04-29 | — | — | US | disclosed |
| US-8710221-B2 | Process and intermediates for preparing lapatinib | SCINOPHARM TAIWAN, LTD. (TW) | 2014-04-29 | — | — | US | disclosed |
| US-20140024829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB | SCINOPHARM TAIWAN, LTD. (TW) | 2014-01-23 | — | — | US | disclosed |
| US-20140024829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB | SCINOPHARM TAIWAN, LTD. (TW) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB | EGFR, ABL1, ERBB2 | PDE4A 4501/4885PDE4B 4370/4885PDE4C 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.